Literature DB >> 35226254

Aberrant Bone Regulation in Albright Hereditary Osteodystrophy dueto Gnas Inactivation: Mechanisms and Translational Implications.

Patrick McMullan1,2, Emily L Germain-Lee3,4,5.   

Abstract

PURPOSE OF REVIEW: This review highlights the impact of Gnas inactivation on both bone remodeling and the development of heterotopic subcutaneous ossifications in Albright hereditary osteodystrophy (AHO). Here we discuss recent advancements in understanding the pathophysiologic mechanisms of the aberrant bone development in AHO as well as potential translational implications. RECENT
FINDINGS: Gnas inactivation can regulate the differentiation and function of not only osteoblasts but also osteoclasts and osteocytes. Investigations utilizing a mouse model of AHO generated by targeted disruption of Gnas have revealed that bone formation and resorption are differentially affected based upon the parental origin of the Gnas mutation. Data suggest that Gnas inactivation leads to heterotopic bone formation within subcutaneous tissue by changing the connective tissue microenvironment, thereby promoting osteogenic differentiation of tissue-resident mesenchymal progenitors. Observed variations in bone formation and resorption based upon the parental origin of the Gnas mutation warrant future investigations and may have implications in the management and treatment of AHO and related conditions. Additionally, studies of heterotopic bone formation due to Gnas inactivation have identified an essential role of sonic hedgehog signaling, which could have therapeutic implications not only for AHO and related conditions but also for heterotopic bone formation in a wide variety of settings in which aberrant bone formation is a cause of significant morbidity.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bone remodeling; Gnas; Heterotopic ossification; Osteoblast; Osteoclast; Osteocyte

Mesh:

Substances:

Year:  2022        PMID: 35226254     DOI: 10.1007/s11914-022-00719-w

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  61 in total

1.  Pseudo-pseudohypoparathyroidism.

Authors:  F ALBRIGHT; A P FORBES; P H HENNEMAN
Journal:  Trans Assoc Am Physicians       Date:  1952

Review 2.  Pseudohypoparathyroidism.

Authors:  Agnès Linglart; Michael A Levine; Harald Jüppner
Journal:  Endocrinol Metab Clin North Am       Date:  2018-10-12       Impact factor: 4.741

Review 3.  Imprinting in Albright's hereditary osteodystrophy.

Authors:  S J Davies; H E Hughes
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318

4.  Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein.

Authors:  M A Levine; R W Downs; A M Moses; N A Breslau; S J Marx; R D Lasker; R E Rizzoli; G D Aurbach; A M Spiegel
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

5.  Reproductive dysfunction in women with Albright's hereditary osteodystrophy.

Authors:  A B Namnoum; G R Merriam; A M Moses; M A Levine
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

Review 6.  An update on the clinical and molecular characteristics of pseudohypoparathyroidism.

Authors:  Michael A Levine
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-12       Impact factor: 3.243

7.  Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a.

Authors:  Emily L Germain-Lee; Chang Lin Ding; Zhichao Deng; Janet L Crane; Motoyasu Saji; Matthew D Ringel; Michael A Levine
Journal:  Biochem Biophys Res Commun       Date:  2002-08-09       Impact factor: 3.575

Review 8.  Physiological functions of the imprinted Gnas locus and its protein variants Galpha(s) and XLalpha(s) in human and mouse.

Authors:  Antonius Plagge; Gavin Kelsey; Emily L Germain-Lee
Journal:  J Endocrinol       Date:  2008-02       Impact factor: 4.286

Review 9.  Management of pseudohypoparathyroidism.

Authors:  Emily L Germain-Lee
Journal:  Curr Opin Pediatr       Date:  2019-08       Impact factor: 2.856

Review 10.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.